DRUG · Mapped RxNorm record
Pemetrexed
Normalized identity: pemetrexedView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
NCT00949650
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
BIBW 2992
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Cisplatin
Normalized identity: cisplatinView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedBIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
PemetrexedDRUG · verified · RxNorm: pemetrexed
BIBW 2992DRUG
CisplatinDRUG · verified · RxNorm: cisplatin
Sponsors & collaborators
Boehringer Ingelheimlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00949650 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.